Publications 2011

Abou-Ayache, R., M. Buchler, P. Le Pogamp, P. F. Westeel, Y. Le Meur, I. Etienne, B. Hurault de Ligny, O. Toupance, S. Caillard, G. Sinnasse-Raymond, and G. Touchard. 2011. The influence of cytomegalovirus infections on patient and renal graft outcome: a 3-year, multicenter, observational study (Post-ECTAZ Study). Transplant Proc 43:2630.

Angoulvant, D., F. Ivanes, R. Ferrera, P. G. Matthews, S. Nataf, and M. Ovize. 2011. Mesenchymal stem cell conditioned media attenuates in vitro and ex vivo myocardial reperfusion injury. J Heart Lung Transplant 30:95.Angoulvant, D., I. Sanchez, and L. Boussel. 2011. Late diagnosis of incomplete Cantrell's syndrome on CT scan. Arch Cardiovasc Dis 104:208.

Benz-de Bretagne, I., R. Respaud, P. Vourc'h, J. M. Halimi, A. Caille, J. S. Hulot, C. R. Andres, and C. Le Guellec. 2011. Urinary elimination of coproporphyrins is dependent on ABCC2 polymorphisms and represents a potential biomarker of MRP2 activity in humans. J Biomed Biotechnol 2011:498757.

Bobin-Dubigeon, C., A. Heurgue-Berlot, O. Bouche, M. B. Amiand, C. Le Guellec, and J. M. Bard. 2011. A new rapid and sensitive LC-MS assay for the determination of sorafenib in plasma: application to a patient undergoing hemodialysis. Ther Drug Monit 33:705.

Bonnet, F., E. Gauthier, H. Gin, S. Hadjadj, J. M. Halimi, T. Hannedouche, V. Rigalleau, D. Romand, R. Roussel, and P. Zaoui. 2011. Expert consensus on management of diabetic patients with impairment of renal function. Diabetes Metab 37 Suppl 2:S1.

Bonvalet, M., E. Wambre, H. Moussu, S. Horiot, W. W. Kwok, A. Louise, D. Ebo, C. Hoarau, L. Van Overtvelt, V. Baron-Bodo, and P. Moingeon. 2011. Comparison between major histocompatibility complex class II tetramer staining and surface expression of activation markers for the detection of allergen-specific CD4(+) T cells. Clin Exp Allergy 41:821.

Boulamery, A., N. Venisse, and C. Le Guellec. 2011. [Level of evidence for therapeutic drug monitoring of teicoplatin]. Therapie 66:45. Charles, M., C. Le Guellec, D. Richard, and F. Libert. 2011. [Level of evidence for therapeutic drug monitoring of itraconazole]. Therapie 66:103.

de Menthon, M., P. Cohen, C. Pagnoux, M. Buchler, J. Sibilia, F. Detree, M. Gayraud, M. Khellaf, C. Penalba, B. Legallicier, L. Mouthon, and L. Guillevin. 2011. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clin Exp Rheumatol 29:S63.

Garot, D., R. Respaud, P. Lanotte, N. Simon, E. Mercier, S. Ehrmann, D. Perrotin, P. F. Dequin, and C. Le Guellec. 2011. Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal. Br J Clin Pharmacol 72:758.Hulin, A., E. Dailly, and C. Le Guellec. 2011. [Level of evidence for therapeutic drug monitoring of voriconazole]. Therapie 66:109.Humar, A., P. Peeters, D. Abramowicz, Y. Lebranchu, I. Hauser, A. Jardine, A. P. Limaye, F. Vincenti, J. D. Punch, and E. Blumberg. 2011. Response to questions regarding the design and results of the IMPACT trial. Am J Transplant 11:177.

Joannides, R., C. Monteil, B. H. de Ligny, P. F. Westeel, M. Iacob, E. Thervet, S. Barbier, J. Bellien, Y. Lebranchu, S. G. Seguin, C. Thuillez, M. Godin, and I. Etienne. 2011. Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. Am J Transplant 11:2414.

Kofman, T., P. Grimbert, F. Canoui-Poitrine, J. Zuber, V. Garrigue, C. Mousson, L. Frimat, N. Kamar, G. Couvrat, N. Bouvier, L. Albano, A. Le Thuaut, E. Pillebout, G. Choukroun, L. Couzi, J. Peltier, C. Mariat, M. Delahousse, M. Buchler, P. Le Pogamp, F. Bridoux, C. Pouteil-Noble, P. Lang, and V. Audard. 2011. Renal transplantation in patients with AA amyloidosis nephropathy: results from a French multicenter study. Am J Transplant 11:2423.

Le Meur, Y., A. Thierry, F. Glowacki, J. P. Rerolle, V. Garrigue, N. Ouali, A. E. Heng, M. Delahousse, L. Albano, P. Lang, L. Couzi, M. Jaureguy, Y. Lebranchu, C. Mousson, D. Glotz, M. Kessler, F. Vrtovsnik, S. Rouanet, N. Tagieva, and N. Kamar. 2011. Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil. Transplantation 92:1244.

Lefeuvre, S., M. L. Jelassi, A. Benlmouden, M. Berge, C. Le Guellec, and E. M. Billaud. 2011. [Level of evidence for therapeutic drug monitoring of posaconazole]. Therapie 66:115

Saulnier, P. J., R. Roussel, J. M. Halimi, J. Lebrec, D. Dardari, S. Maimaitiming, G. Guilloteau, X. Prugnard, R. Marechaud, S. Ragot, M. Marre, and S. Hadjadj. 2011. Impact of natriuretic peptide clearance receptor (NPR3) gene variants on blood pressure in type 2 diabetes. Diabetes Care 34:1199.

Vargas-Poussou, R., K. Dahan, D. Kahila, A. Venisse, E. Riveira-Munoz, H. Debaix, B. Grisart, F. Bridoux, R. Unwin, B. Moulin, J. P. Haymann, M. C. Vantyghem, C. Rigothier, B. Dussol, M. Godin, H. Nivet, L. Dubourg, I. Tack, A. P. Gimenez-Roqueplo, P. Houillier, A. Blanchard, O. Devuyst, and X. Jeunemaitre. 2011. Spectrum of mutations in Gitelman syndrome. J Am Soc Nephrol 22:693.

Venisse, N., and C. Le Guellec. 2011. [Level of evidence for therapeutic drug monitoring of fluconazole]. Therapie 66:97.

Wambre, E., M. Bonvalet, V. B. Bodo, B. Maillere, G. Leclert, H. Moussu, E. Von Hofe, A. Louise, A. M. Balazuc, D. Ebo, C. Hoarau, G. Garcia, L. Van Overtvelt, and P. Moingeon. 2011. Distinct characteristics of seasonal (Bet v 1) vs. perennial (Der p 1/Der p 2) allergen-specific CD4(+) T cell responses. Clin Exp Allergy 41:192.

Lebranchu Y, Thierry A, Thervet E, Büchler M, Etienne I, Westeel PF, Hurault de Ligny B, Moulin B, Rérolle JP, Frouget T, Girardot-Seguin S, Toupance O. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study. Am J Transplant. 2011 Aug;11:1665-75

Gatault P, Jollet I, Rabot N, Boulanger MD, Taupin JL, Barbet C, Baron C, Thierry A, Halimi JM, Lebranchu Y, Touchard G, Büchler M. Mothers without HLA antibodies before transplantation have a low risk of alloimmunization post-transplantation. Tissue Antigens. 2011 Oct;78:241-8.

Gatault P, Al-Najjar A, Barbet C, Roland M, Laouad I, Buchler M, Marlière JF, Métais PE, Clément A, Nivet H, Lebranchu Y, Halimi JM. Doubling of serum creatinine in clinical trials, cost-effectiveness studies, and individual patients: adequate use in renal transplantation. Transplantation. 2011 Nov 15;92(9):1012-7.

Pereira H, Buchler M, Brichart N, Haillot O, d'Arcier BF, Braguet R, Boutin JM, Bruyère F. [Ureteral stenosis after renal transplantation: Risk factors and impact on survival]. Prog Urol. 2011 Jun;21(6):389-96.

Pourrat X, Sipert AS, Sautenet B, Merieau E, Grassin J, Halimi JM. Drugs adjustment dosage at hospital discharge for patients with renal failure: Study of 326 medical records. Presse Med. 2011 Dec 22. [Epub ahead of print]

Halimi JM. Albuminuria, proteinuria, and graft survival in kidney transplantation. Am J Kidney Dis. 2011 Dec;58(6):1037

Halimi JM, Sautenet B, Gatault P, Roland M, Giraudeau B. Renal endpoints in renal and cardiovascular randomized clinical trials: time for a consensus. Fundam Clin Pharmacol. 2011 Aug 19. doi: 10.1111.